RPRX · NASDAQ
Royalty Pharma (RPRX) Stock Price & Fundamentals
Royalty Pharma (RPRX) closed at $353.53 on Oct 9, 2026, up 0.17% from the previous close of $352.94.
Share price, past year
1Y +35.99%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $353.53 |
| Sep 30, 2026 | $348.93 |
| Aug 31, 2026 | $338.33 |
| Jul 31, 2026 | $330.16 |
| Jun 30, 2026 | $311.93 |
| May 29, 2026 | $294.84 |
| Apr 30, 2026 | $292.48 |
| Mar 31, 2026 | $268.51 |
| Feb 27, 2026 | $262.97 |
| Jan 30, 2026 | $251.06 |
| Dec 31, 2025 | $244.40 |
| Nov 28, 2025 | $266.63 |
| Oct 31, 2025 | $265.89 |
Key statistics
- Market cap
- —
- P/E (TTM)
- 189.1
- EPS (TTM)
- $1.87
- Revenue (TTM)
- $2.54B
- Net income (TTM)
- $812.00M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $244.40 – $357.61
Financials
Royalty Pharma reported revenue of $2.38B for fiscal 2025, up 5.06% from fiscal 2024.
Royalty Pharma earned net income of $770.95M in fiscal 2025, a net margin of 32.4%.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.38B | +5.1% | $770.95M | 32.4% | $1.78 | — |
| FY2024ended Dec 31, 2024 | $2.26B | −3.9% | $858.98M | 38.0% | $1.91 | — |
| FY2023ended Dec 31, 2023 | $2.35B | +5.2% | $1.13B | 48.2% | $2.53 | — |
| FY2022ended Dec 31, 2022 | $2.24B | −2.3% | $42.83M | 1.9% | $0.10 | — |
| FY2021ended Dec 31, 2021 | $2.29B | +7.9% | $619.73M | 27.1% | $1.49 | — |
| FY2020ended Dec 31, 2020 | $2.12B | +17.0% | $975.04M | 45.9% | $1.32 | — |
| FY2019ended Dec 31, 2019 | $1.81B | +1.1% | $2.35B | 129.5% | — | — |
| FY2018ended Dec 31, 2018 | $1.79B | — | $1.38B | 76.8% | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $674.14M | $17.88M | $0.04 |
| Q1 FY2026ended Mar 31, 2026 | $630.58M | $294.69M | $0.67 |
| Q4 FY2025ended Dec 31, 2025 | $621.99M | $211.21M | $0.49 |
| Q3 FY2025ended Sep 30, 2025 | $609.29M | $288.22M | $0.67 |
| Q2 FY2025ended Jun 30, 2025 | $578.67M | $32.18M | $0.07 |
| Q1 FY2025ended Mar 31, 2025 | $568.25M | $239.35M | $0.55 |
| Q4 FY2024ended Dec 31, 2024 | $593.64M | $208.21M | $0.46 |
| Q3 FY2024ended Sep 30, 2024 | $564.69M | $543.99M | $1.21 |
Company profile
- Name
- Royalty Pharma plc
- Ticker
- RPRX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 110 East 59th Street, New York, NY 10022
- Incorporated in
- X0
- Fiscal year ends
- December
- SEC CIK
- 0001802768
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jun 4, 2026
- May 28, 2026
- May 6, 2026
- May 6, 2026
- Apr 13, 2026
- Feb 11, 2026
Frequently asked questions
What is Royalty Pharma's stock price?
Royalty Pharma (RPRX) closed at $353.53 on Oct 9, 2026, up 0.17% from the previous close of $352.94.
How much revenue does Royalty Pharma make?
Royalty Pharma reported revenue of $2.38B for fiscal 2025, up 5.06% from fiscal 2024.
What is RPRX's P/E ratio?
Royalty Pharma's price-to-earnings ratio is 189.1, based on trailing twelve-month diluted EPS of $1.87.
Does Royalty Pharma pay a dividend?
Royalty Pharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Royalty Pharma plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures